The DOI matches its Crossref record; 70 of the 75 references it cites were found in a registry or an index.
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
Abstract
The oxycyclohexyl acid BMS-986278 ( 33 ) is a potent lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, with a human LPA 1 K b of 6.9 nM. The structure–activity relationship (SAR) studies starting from the LPA 1 antagonist clinical compound BMS-986020 ( 1 ), which culminated in the discovery of 33, are discussed. The detailed in vitro and in vivo preclinical pharmacology profiles of 33, as well as its pharmacokinetics/metabolism profile, are described. On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclinical species, 33 was advanced into clinical trials, including an ongoing Phase 2 clinical trial in patients with lung fibrosis (NCT04308681).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [105]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry
Chinchilla, R., & Nájera, C. (2007) · Chemical Reviews · doi:10.1021/cr050992x · Cited by 2,974
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Ishiyama, T., Murata, M., & Miyaura, N. (1995) · The Journal of Organic Chemistry · doi:10.1021/jo00128a024 · Cited by 1,590
Mitsunobu and Related Reactions: Advances and Applications
Swamy, K. C. K., Kumar, N. N. B., Balaraman, E., & Kumar, K. V. P. P. (2009) · Chemical Reviews · doi:10.1021/cr800278z · Cited by 1,184
Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides
Zhang, L., Chen, X., Xue, P., Sun, H. H. Y., Williams, I. D., Sharpless, K. B., Fokin, V. V., & Jia, G. (2005) · Journal of the American Chemical Society · doi:10.1021/ja054114s · Cited by 1,120
Self-citationRitchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Cited by
An Analysis of Successful Hit-to-Clinical Candidate Pairs
Brown, D. G. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00521 · Cited by 59
Gill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
Self-citationCheng, X., Jiang, S., Pan, B., Xie, W., & Meng, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01964-3 · Cited by 40
Base‐Modulated 1,3‐Regio‐ and Stereoselective Carboboration of Cyclohexenes
Kong, W., Bao, Y., Lu, L., Han, Z., Zhong, Y., Zhang, R., Li, Y., & Yin, G. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202308041 · Cited by 34
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 28
“A phase I trial of BBT-877 in 80 healthy volunteers resulted in only mild AEs and no serious AEs [87].”
Background
Metadata
- Authors
- Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., Dhanusu, S., Reddigunta, R., Kumaravel, S., Jusuf, S., Smith, D., Krishnananthan, S., Li, J., Wang, T., Heiry, R., Sum, C. S., Kalinowski, S. S., Hung, C.-P., Chu, C.-H., Azzara, A. V., Ziegler, M., Burns, L., Zinker, B. A., Boehm, S., Taylor, J., Sapuppo, J., Mosure, K., Everlof, G., Guarino, V., Zhang, L., Yang, Y., Ruan, Q., Xu, C., Apedo, A., Traeger, S. C., Cvijic, M. E., Lentz, K. A., Tirucherai, G., Sivaraman, L., Robl, J., Ellsworth, B. A., Rosen, G., Gordon, D. A., Soars, M. G., Gill, M., & Murphy, B. J.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Biocon-Bristol Myers Squibb Research & Development Center, Bangalore 560099, India
- Cardiovascular & Fibrosis Discovery Biology, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
- Corresponding author
- Cheng, Peter T. W.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-28
- Volume
- 64
- Issue
- 21
- Pages
- 15549-15581
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3209712727
- Cited by
- 61
- References
- 75
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 23 · 2023: 13 · 2022: 3 · 2021: 2
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- LPAR1, pulmonary fibrosis, structure-activity relationship, pharmacokinetics, ADME, drug discovery
- MeSH terms
- Animals, Dose-Response Relationship, Drug, Male, Pulmonary Fibrosis, Structure-Activity Relationship, Molecular Structure, Rats, Sprague-Dawley, Receptors, Lysophosphatidic Acid, Mice, Rats, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01256
- The paper
- Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., Dhanusu, S., Reddigunta, R., Kumaravel, S., Jusuf, S., Smith, D., Krishnananthan, S., Li, J., Wang, T., Heiry, R., . . . Murphy, B. J. (2021). Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.